CO5261629A1 - ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS - Google Patents
ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERSInfo
- Publication number
- CO5261629A1 CO5261629A1 CO01011989A CO01011989A CO5261629A1 CO 5261629 A1 CO5261629 A1 CO 5261629A1 CO 01011989 A CO01011989 A CO 01011989A CO 01011989 A CO01011989 A CO 01011989A CO 5261629 A1 CO5261629 A1 CO 5261629A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkenyl
- group
- alkynyl
- cycloalkyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto que tiene la Fórmula I: <EMI FILE="01011989_1" ID="1" IMF=JPEG >y las sales y precursores de drogas farmacéuticamente aceptables de éste, en dondeR1 y R2 son cada uno independientemente seleccionados del grupo conformado por H, F, alquil C1-5, alquenil C2-5, y alquinil C2-5, en donde dichos grupos alquil, alquenil, y alquinil pueden ser lineales ó ramificados y van opcionalmente sustituidos con 1-3 átomos de halógeno; u opcionalmente R1 y R2 juntos forman un cicloalquil C3-6;R3 y R4 son cada uno independientemente seleccionados del grupo conformado por alquil C1-5, alquenil C2-5, alquinil C2-5, y cloro, a condición de que R3 y R4 no sean ambos cloro, en donde dichos grupos alquil, alquenil, y alquinil pueden ser lineales ó ramificados y van opcionalmente sustituidos con 1-5 átomos de flúor;X es N ó CR; Y es O, S, ó NR; Z es O ó S;Cada R es independientemente seleccionado del grupo conformado por H, alquil C1-5, alquenil C2-5, y alquinil C2-5, en donde dichos alquil, alquenil, y alquinil pueden ser lineales ó ramificados y van opcionalmente sustituidos con 1-5 átomos de flúor y/o con un grupo -O-alquil C1-3, en donde dicho grupo -O-alquil C1-3 se encuentra opcionalmente sustituido con 1-7 átomos de flúor; yR5 se selecciona del grupo conformado por H, alquil C1-6, alquenil C2-6, alquinil C2-6, Aril C6-10, -O-alquil C1-6, -O-alquenil C2-6, -O-alquinil C2-6, -O-Aril C6-10, Cicloalquil C3-6, Heterociclil de 5-6 miembros, Heteroaril de 5-6 miembros, -O-Cicloalquil C3-6, -O-Heterociclil de 5-6 miembros, -O-Heteroaril de 5-6 miembros, y un grupo alquil C1-4 el cual comprende en una posición que interrumpe la cadena, ó al final de la cadena, un grupo seleccionado entre Aril C6-10, Cicloalquil C3-6, Heterociclil de 5-6 miembros, y Heteroaril de 5-6 miembros, en donde cada uno de dichos grupos alquil, alquenil, alquinil, -O-alquil, -O-alquenil, y -O-alquinil es lineal o ramificado y va opcionalmente sustituido con 1-5 átomos de flúor y/o con un grupo -OCH3 ó -OCF3, y cada uno de dichos grupos Aril, Cicloalquil, Heteroaril, Heterociclil, -O-Aril, -O-Cicloalquil, -O-Heteroaril, y -O-Heterociclil va opcionalmente sustituido con 1-7 átomos de halógeno y/o con un grupo -OCH3 ó -OCF3.A compound having Formula I: <EMI FILE = "01011989_1" ID = "1" MFI = JPEG> and pharmaceutically acceptable drug salts and precursors thereof, where R1 and R2 are each independently selected from the group consisting of H , F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl groups can be linear or branched and are optionally substituted with 1-3 halogen atoms; or optionally R1 and R2 together form a C3-6 cycloalkyl; R3 and R4 are each independently selected from the group consisting of C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 they are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups can be linear or branched and are optionally substituted with 1-5 fluorine atoms, X is N or CR; Y is O, S, or NR; Z is O or S; Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl can be linear or branched and optionally go substituted with 1-5 fluorine atoms and / or with a -O-C1-3 alkyl group, wherein said -O-C1-3 alkyl group is optionally substituted with 1-7 fluorine atoms; and R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, -O-C1-6 alkyl, -O-C2-6 alkenyl, -O-C2 alkynyl -6, -O-C6-10 aryl, C3-6 cycloalkyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl, -O-C3-6 cycloalkyl, 5-6 membered -O-heterocyclyl, -O - 5-6-member heteroaryl, and a C1-4 alkyl group which comprises in a position that disrupts the chain, or at the end of the chain, a group selected from Aril C6-10, C3-6 cycloalkyl, 5-heterocyclyl -6 members, and 5-6-member heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, -O-alkyl, -O-alkenyl, and -O-alkynyl groups is linear or branched and is optionally substituted with 1 -5 fluorine atoms and / or with a group -OCH3 or -OCF3, and each of said groups Aril, Cycloalkyl, Heteroaryl, Heterocyclyl, -O-Aryl, -O-Cycloalkyl, -O-Heteroaryl, and -O- Heterocyclyl is optionally substituted with 1-7 halogen atoms and / or with a group -OCH3 or -OCF3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18359300P | 2000-02-18 | 2000-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261629A1 true CO5261629A1 (en) | 2003-03-31 |
Family
ID=22673475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01011989A CO5261629A1 (en) | 2000-02-18 | 2001-02-15 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1259494A4 (en) |
| JP (1) | JP2003523336A (en) |
| AU (1) | AU784722B2 (en) |
| CA (1) | CA2400021A1 (en) |
| CO (1) | CO5261629A1 (en) |
| PE (1) | PE20011056A1 (en) |
| WO (1) | WO2001060807A1 (en) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| SE0000772D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SK288217B6 (en) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Composition, therapeutic combination, pharmaceutical preparation and use thereof |
| BRPI0206641B8 (en) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | use of a sterol absorption inhibitor |
| US7091230B2 (en) | 2001-02-09 | 2006-08-15 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| WO2003022286A1 (en) | 2001-09-08 | 2003-03-20 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| NZ531917A (en) | 2001-09-14 | 2006-01-27 | Japan Tobacco Inc | Linked biaryl compounds |
| DE60216300T2 (en) | 2001-09-21 | 2007-06-28 | Schering Corp. | TREATMENT OF XANTHOM BY AZETIDINONE DERIVATIVES AS AN INHIBITOR OF STEROL ABSORPTION |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| WO2003045382A1 (en) * | 2001-11-21 | 2003-06-05 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| WO2003066581A1 (en) * | 2002-02-05 | 2003-08-14 | Eli Lilly And Company | Urea linker derivatives for use as ppar modulators |
| CA2481371A1 (en) * | 2002-03-11 | 2003-09-18 | Peter Zahradka | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| AU2003225027A1 (en) * | 2002-04-16 | 2003-11-03 | Merck And Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| WO2004017967A1 (en) * | 2002-08-22 | 2004-03-04 | Cornell Research Foundation, Inc. | Multifunctional cox-2 inhibitors |
| PL376470A1 (en) * | 2002-10-21 | 2005-12-27 | Janssen Pharmaceutica N.V. | Treating syndrome x with substituted tetralins and indanes |
| EA009553B1 (en) * | 2002-10-21 | 2008-02-28 | Янссен Фармацевтика Н.В. | Substituted tetralins and indanes |
| CA2502665A1 (en) * | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes and their use |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| ATE404191T1 (en) * | 2002-12-10 | 2008-08-15 | Novartis Pharma Ag | COMBINATIONS OF A DPP-IV INHIBITOR AND A PPAR-ALPHA AGONIST |
| HRP20050696B1 (en) | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| NL1022443C2 (en) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipids for improving the composition of the intestinal flora. |
| DE602004020316D1 (en) | 2003-01-20 | 2009-05-14 | Tno | THE USE OF SPHINGOLIPIDS TO REDUCE THE CHOLESTEROL AND TRIGLYZERID MIRRORS IN PLASMA. |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| ES2311806T3 (en) | 2003-03-07 | 2009-02-16 | Schering Corporation | AZETIDINONA COMPOSITE SUBSTITUTED, FORNULATIONS AND USES OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA. |
| CN1756756A (en) | 2003-03-07 | 2006-04-05 | 先灵公司 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| EP1457206A1 (en) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| SE0301009D0 (en) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (en) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| SA04250253B1 (en) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20070207983A1 (en) * | 2004-03-16 | 2007-09-06 | Nieuwenhuizen Willem F | Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome |
| EP1576894A1 (en) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
| US7968723B2 (en) | 2004-05-05 | 2011-06-28 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| WO2006033891A2 (en) * | 2004-09-16 | 2006-03-30 | Merck & Co., Inc. | Compounds for the treatment of dyslipidemia and other lipid disorders |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| UY29223A1 (en) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | PHENOXYACETIC ACIDS REPLACED, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION |
| AU2005310341A1 (en) | 2004-11-30 | 2006-06-08 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
| WO2006059744A1 (en) * | 2004-11-30 | 2006-06-08 | Nippon Chemiphar Co., Ltd. | ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ |
| CN102584754B (en) * | 2005-03-04 | 2016-02-03 | 默沙东公司 | There is the fused aromatic compounds of anti-diabetic activity |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| CA2613365C (en) | 2005-06-30 | 2013-08-13 | Novo-Nordisk A/S | Phenoxy acetic acids as ppar delta activators |
| FR2890071B1 (en) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | NEW INDOLE COMPOUNDS |
| FR2890072A1 (en) | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | New pyrrolopyridine derivatives are peroxisome proliferator activated receptor activators useful to treat e.g. hypertriglyceridimia, hyperlipidemia, hypercholesterolemia and diabetes |
| EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| NZ568488A (en) | 2005-12-22 | 2011-07-29 | High Point Pharmaceuticals Llc | Phenoxy acetic acids as PPAR delta activators |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| CA2688187C (en) | 2007-05-07 | 2016-10-11 | Merck & Co., Inc. | Method of treament using fused aromatic compounds having anti-diabetic activity |
| UA100983C2 (en) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Biphenyloxypropanoic acid as crth2 modulator and intermediates |
| WO2009107387A1 (en) | 2008-02-29 | 2009-09-03 | 興和株式会社 | 2-oxochromene derivative |
| JP2013006769A (en) * | 2009-10-08 | 2013-01-10 | Nippon Chemiphar Co Ltd | Activator for peroxisome proliferator activating receptor |
| MX2013003184A (en) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto. |
| KR101890959B1 (en) | 2010-11-04 | 2018-08-22 | 알비레오 에이비 | Ibat inhibitors for the treatment of liver diseases |
| JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
| EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
| CN106659726A (en) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | Solid preparation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (en) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN112449637B (en) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | Benzothiazepine compounds and their use as bile acid modulators |
| BR112020024762A2 (en) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | methods of treating conditions related to the s1p1 receptor |
| SG11202012151XA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Crystal modifications of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| MX2021008981A (en) | 2019-02-06 | 2021-09-08 | Albireo Ab | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS. |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| EP4069360B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP7696898B2 (en) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators - Patents.com |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761080B (en) | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | Benzothia(di)azepine compounds and their use as bile acid regulators |
| CN111793066B (en) * | 2020-07-17 | 2022-04-08 | 瀚海新拓(杭州)生物医药有限公司 | Benzo five-membered heterocyclic sulfonamide compound, preparation method thereof, pharmaceutical composition and application |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (en) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728662A (en) * | 1977-11-21 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | 1,2-benzisoxazoloxyacetic acids and related compounds |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
-
2001
- 2001-02-14 EP EP01910624A patent/EP1259494A4/en not_active Withdrawn
- 2001-02-14 JP JP2001560192A patent/JP2003523336A/en not_active Withdrawn
- 2001-02-14 CA CA002400021A patent/CA2400021A1/en not_active Abandoned
- 2001-02-14 WO PCT/US2001/004636 patent/WO2001060807A1/en not_active Ceased
- 2001-02-14 AU AU38214/01A patent/AU784722B2/en not_active Ceased
- 2001-02-15 CO CO01011989A patent/CO5261629A1/en not_active Application Discontinuation
- 2001-02-16 PE PE2001000178A patent/PE20011056A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003523336A (en) | 2003-08-05 |
| EP1259494A1 (en) | 2002-11-27 |
| CA2400021A1 (en) | 2001-08-23 |
| EP1259494A4 (en) | 2004-09-15 |
| AU3821401A (en) | 2001-08-27 |
| WO2001060807A1 (en) | 2001-08-23 |
| PE20011056A1 (en) | 2001-10-22 |
| AU784722B2 (en) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261629A1 (en) | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | |
| ATE478685T1 (en) | PRODRUGS WITH NEW BIOcleavable Compounds | |
| CY1112733T1 (en) | IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AND ANTI-VIRTUAL METHODS | |
| AR046202A1 (en) | NUCLEOSIDIC COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| CY1117299T1 (en) | COANS, METHOD FOR PREPARATION OF THESE AND HARMFUL PEST CONTROLLED AGENTS CONTAINING THEM | |
| MA22344A1 (en) | PROCESS FOR THE PREPARATION OF NEW ERYTHROMICIN DERIVATIVES | |
| ATE249462T1 (en) | NEW CRYSTALLINE FORM OF N-(4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO(2,3-D)-PYRIMIDINE-5- YL)ETHYL)BENZOYL)-L -GLUTAMIC ACID AND PROCESS FOR THE PRODUCTION THEREOF | |
| WO2007048064A3 (en) | Amino-pyrimidines as casein kinase ii (ck2) modulators | |
| AR016351A1 (en) | BETA CRYSTAL FORM OF THE METANSULPHONIC ACID ADDITION SALT OF 4- (4-METHYLPIPERAZIN-1-ILMETIL) -N- [4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL] BENZAMIDE, PHARMACEUTICAL COMPOSITION, USE OF CRYSTAL FORM FOR THE PREPARATION OF A PHARMACOLOGICAL AGENT, AND PROCESSES FOR PREPARATION | |
| CO5570667A2 (en) | SUBSTITUTED SUBSTITUTE SUBSTITUTED SUBSTITUTE COMPOUNDS WITH HETEROARILO FOR THE TREATMENT OF DISEASES | |
| ATE398125T1 (en) | QUINAZOLINE DERIVATIVES AS TGF BETA INHIBITORS | |
| ECSP055696A (en) | 2-HYDROXI-1, 3-DIAMINOALCAN OIL | |
| BR0210122A (en) | Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same | |
| AR049126A1 (en) | DERIVATIVES OF 5, 6, 7, 8 - TETRAHYDROIMIDAZO [1,5A] PIRIDINE WITH INHIBITORY ACTIVITY OF ALDOSTERONE SYNTHEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF HYPERALDOSINDISM. | |
| AR053774A1 (en) | DERIVATIVES OF SULFONILBENCIMIDAZOL. PHARMACEUTICAL COMPOSITIONS. | |
| BR0212484A (en) | Compound, process for the preparation and use thereof, method of treating eating disorders in a warm-blooded animal, and pharmaceutical composition | |
| AR064702A1 (en) | PROTEIN G HETEROCICLIC RECEPTORS AGONISTS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND METABOLIC DISORDERS. | |
| CO5570675A2 (en) | BENZIMIDAZOLO SUBSTITUTED COMPOUNDS AND ITS USE FOR CANCER TREATMENT | |
| JP2018525342A5 (en) | ||
| DE602006018467D1 (en) | Fast-dissolving formulation of non-steroidal anti-inflammatory drugs | |
| ATE97810T1 (en) | INJECTABLE CEPHALOSPORIN PRODUCTS AND THEIR USE. | |
| BRPI0607214B8 (en) | hiv inhibitors 2-(4-cyanophenylamino)pyrimidine derivatives, pharmaceutical composition comprising them and their preparation processes | |
| PT97407A (en) | METHOD FOR THE PREPARATION OF (R) -9- {2- (PHOSPHO-METHOXY) -PROPYL} -GUANINE | |
| RU2007134564A (en) | HIV INHIBITING DERIVATIVES OF 2- (4-CYANOPHENYLAMINO) -PYRIMIDINE OXIDE | |
| AR052909A1 (en) | CRYSTAL BASE OF TRANS-1 - ((1R, 3S) -6-CHLORO-3-FENILINDAN-1-IL) -3,3-DIMETHYLIPIPERAZINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |